Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial (Q33390705)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial |
scientific article |
Statements
1 reference
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial (English)
1 reference
P A Fasching
1 reference
S Loibl
1 reference
M Untch
1 reference
G von Minckwitz
1 reference
H Eidtmann
1 reference
J-U Blohmer
1 reference
S-D Costa
1 reference
R Kreienberg
1 reference
J Hilfrich
1 reference
B Gerber
1 reference
C Hanusch
1 reference
T Fehm
1 reference
D Strumberg
1 reference
C Solbach
1 reference
V Nekljudova
1 reference
German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie-Brust investigators
1 reference
1 reference
Identifiers
1 reference